Menu
← Oncology Approval Tracker
FDA DECISION ·
Voranigo
vorasidenib · Servier Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults and children aged 12 years and older with grade 2 astrocytoma or oligodendroglioma and a susceptible IDH1 or IDH2 mutation after surgery, including biopsy or partial or complete resection.
LAMPGEN ANALYSIS
Why it matters
The brain-penetrant IDH inhibitor adds a postoperative option for a defined grade 2 glioma population.
What research teams should watch
Preserve the molecular pathology and surgical history, and coordinate serial MRI review and liver enzyme monitoring.
PRIMARY RECORDS